WO2018009778A1 - Combinaison de glp-1 et de glp-2 pour le traitement ou la prévention de maladies, troubles et syndromes métaboliques - Google Patents

Combinaison de glp-1 et de glp-2 pour le traitement ou la prévention de maladies, troubles et syndromes métaboliques Download PDF

Info

Publication number
WO2018009778A1
WO2018009778A1 PCT/US2017/041075 US2017041075W WO2018009778A1 WO 2018009778 A1 WO2018009778 A1 WO 2018009778A1 US 2017041075 W US2017041075 W US 2017041075W WO 2018009778 A1 WO2018009778 A1 WO 2018009778A1
Authority
WO
WIPO (PCT)
Prior art keywords
glp
peptides
metabolic
subject
administration
Prior art date
Application number
PCT/US2017/041075
Other languages
English (en)
Inventor
Xinfu GUAN
Xuemei SHI
Original Assignee
Baylor College Of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Of Medicine filed Critical Baylor College Of Medicine
Publication of WO2018009778A1 publication Critical patent/WO2018009778A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present disclosure pertains to therapeutic compositions containing both glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) or their derivatives for treating or preventing a metabolic disease in a subject (such as obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), short- bowel syndrome (SBS), and intestinal deficiency of nutrient absorption after bariatric surgery); for treating or preventing a metabolic disorder in a subject (such as hyperphagia, hyperglycemia, postprandial hyperglycemia, hyperlipidemia, abnormal cholesterol levels, hypertension, increased blood pressure, excess body fat mass, and body adiposity); or for treating or preventing a metabolic syndrome (such as insulin resistance, insulin sensitivity, and glucose intolerance) in a subject.
  • a metabolic disease in a subject such as obesity, type 2 diabetes, non-alcoholic fatty liver disease (NAFLD), nonalcoholic ste
  • the present disclosure pertains to methods of treating or preventing metabolic diseases, disorders or syndromes in a subject by administering the therapeutic compositions of the present disclosure to the subject.
  • the administration of the therapeutic compositions of the present disclosure to the subject can improve the subject's metabolic and physiological status. For instance, in some embodiments, the administration improves postabsorptive insulin sensitivity in the subject. In some embodiments, the administration preserves postprandial glycemic control in the subject.
  • FIGURE 1 illustrates a method of treating or preventing a metabolic disease, disorder or syndrome in a subject by administering a therapeutic composition that includes glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2).
  • GLP-1 glucagon-like peptide 1
  • GLP-2 glucagon-like peptide 2
  • FIGURE 2 shows images of pre-proglucagon (PPG) neurons and GLP-2 receptor (Glp2R)-containing neurons in the brainstem.
  • FIGURE 3 shows images of glucagon (Gcg)-cre expression by a Cre-dependent Rosa26-eGFP reporter.
  • FIGURE 4 shows images and schemes relating to the remote activation of hM3Dq- expressing PPG neurons mapped by c-Fos expression.
  • FIGURE 5 illustrates a protocol for quantifying glucose metabolism and insulin sensitivity.
  • FIGURE 6 shows images and schemes relating to the acute activation of hM3Dq- expressing PPG neurons induced acutely by clozapine-N-oxide (CNO).
  • FIG. 6A shows PPG neurons indicated by mCherry (red) in the brainstem nucleus of the solitary tract (NTS) from the Gcg-Cre mouse locally infected with AAV hM3Dq-mCherry vectors with c-Fos expression (green).
  • FIG. 6B shows hM3Dq-expressing PPG neurons excited by CNO (5 ⁇ ), as illustrated by representative traces of the whole-cell patch clamp.
  • FIG. 6C shows PPG neurons labeled by GFP (green) from the Gcg-Cre: :Rosa26-eGFP mouse brainstem.
  • FIG. 6D shows the location of the brainstem slice.
  • FIGURE 7 shows data indicating that the remote activation of PPG neurons in the NTS enhances glucose tolerance and insulin sensitivity in mice fed regular chow.
  • FIG. 7A shows a 6 hour fasting glucose at 0 and 3.5 hour post injection of CNO (ip 1 mg/kg).
  • Excitatory AAV- hM3Dq-mCherry vectors (100 nL) were injected into the Gcg-Cre mouse brainstem NTS.
  • FIG. 7B shows blood glucose concentration of mice (at 3 weeks post viral injection) measured after ip glucose challenge.
  • CNO (1 mg/kg) was ip injected 30 minutes prior to ip glucose tolerance test (GTT).
  • FIG. 7C shows endogenous glucose production (EGP) during a basal period.
  • FIG. 7D shows that the acute activation of PPG neurons in mice (at 3 weeks post viral injection) augments insulin sensitivity largely by further suppression of EGP and GNG.
  • GIR glucose infusion rate
  • Rd rate of glucose disappearance
  • EGP endogenous glucose production
  • GNG gluconeogenesis.
  • FIGURE 8 shows data indicating that the remote activation of the DVC ChAT neurons enhances insulin sensitivity.
  • FIGURE 9 illustrates a proposed model for the activity of PPG neurons in glycemic control.
  • FIGURE 10 provides data demonstrating that glucose homeostasis and insulin sensitivity are impaired in GLP-1R/2R double knockout mice (DKO mice) that were fed a high fat diet (HFD).
  • the insulin clamp (after a 12 hour fast) and postprandial kinetics (after a 6 hour fast) were performed prior to severe obesity (by 12-wk old). Fasting glucose in mice after overnight fast.
  • n 8 ⁇ 10/ group.
  • FIGURE 13 demonstrates that VSG ameliorates insulin resistance in DIO mice via GLP-1R/2R.
  • Basal glucose was measured in mice after a 12 hour fast.
  • Insulin clamp was performed in 12 hour fasted mice on day 21 after VSG, when BW was not dramatically different.
  • n 8 ⁇ 10/ group. ⁇ , * or **P ⁇ 0.10, 0.05 or 0.01 within genotype between VSG vs sham; ab P ⁇ 0.05 within surgery between genotype.
  • FIGURE 14 provides data indicating that GLP-1R/2R are required for intestinal adaptation in DIO mice after VSG.
  • FIGURE 15 provides data indicating that DKO mice show a high incidence of hepatic steatosis and inflammation.
  • Metabolic diseases, disorders and syndromes provide numerous public health concerns. For instance, obesity and diabetes are escalating global epidemics. Bariatric surgery is recommended as the most effective therapy for morbid obesity and diabetes. In particular, Roux- en-Y gastric bypass (RYGB) and vertical sleeve gastrectomy (VSG), two widely used bariatric procedures, induce diabetes remission independent of weight loss. Furthermore, mechanisms for rapidly restoring glycemic control (GC) and insulin sensitivity (IS) are unknown.
  • RYGB Roux- en-Y gastric bypass
  • VSG vertical sleeve gastrectomy
  • GC glycemic control
  • IS insulin sensitivity
  • Glucagon-like peptides 1 and 2 are co-transcribed and co-translated from the glucagon (Gcg) gene, post-translationally processed, and co-secreted from enteroendocrine L cells in the gut and pre-proglucagon (PPG) neurons in the nucleus of the solitary tract (NTS) of the brainstem in response to nutrients.
  • GLP-1 and GLP-2 are key signals for the brain and pancreas to control energy balance and glucose homeostasis in rodents and humans.
  • the pharmacological action of the brainstem GLP-1 -producing neurons is unknown on glycemic control and insulin sensitivity.
  • GLP-1 and GLP-2 have been individually used to treat obesity, diabetes and gut diseases. Through distinct G protein-coupled receptors (GLP-1R and GLP-2R), GLP-1 augments pancreatic insulin secretion while GLP-2 enhances intestinal cell proliferation. However, the combined use of GLP-1 and GLP-2 for treating metabolic diseases, disorders and syndromes has not been envisioned or demonstrated.
  • the present disclosure pertains to therapeutic compositions containing both glucagon-like peptide 1 (GLP-1) and glucagon-like peptide 2 (GLP-2) or their derivatives for treating or preventing a metabolic disease in a subject (such as obesity, type 2 diabetes, NAFLD, NASH, short-bowel syndrome (SBS), and intestinal deficiency of nutrient absorption after bariatric surgery); for treating or preventing a metabolic disorder in a subject (such as hyperphagia, hyperglycemia, postprandial hyperglycemia, hyperlipidemia, abnormal cholesterol levels, hypertension, increased blood pressure, excess body fat mass, and body adiposity); or for treating or preventing a metabolic syndrome (such as insulin resistance and glucose intolerance) in a subject.
  • the present disclosure pertains to methods of treating or preventing metabolic diseases, disorders or syndromes in a subject by administering the therapeutic compositions of the present disclosure to the subject.
  • the methods and therapeutic compositions of the present disclosure can have various embodiments. For instance, various methods may be utilized to administer the therapeutic compositions of the present disclosure to various subjects in order to treat or prevent various metabolic diseases, metabolic disorders or metabolic syndromes.
  • compositions generally refer to compositions that include GLP-1 and GLP-2.
  • GLP-1 and GLP-2 may be in various forms in the therapeutic compositions of the present disclosure.
  • each of GLP-1 and GLP-2 can be in the form of synthesized peptides, recombinant peptides, secreted peptides, isolated peptides, lyophilized peptides, derivatized peptides, intact peptides, peptide fragments that include one or more receptor binding domains, and combinations of such forms.
  • each of GLP-1 and GLP-2 can be in derivatized form.
  • each of GLP-1 and GLP-2 can include chemically modified amino acid sequences or amino acids conjugated with fatty acids.
  • each of GLP-1 and GLP-2 can be in the form of synthesized peptides. In some embodiments, each of GLP-1 and GLP-2 can be in the form of recombinant peptides.
  • each of GLP-1 and GLP-2 can be in the form of secreted peptides.
  • GLP-1 and GLP-2 may be secreted from nerve cells, endocrine cells, and combinations thereof.
  • GLP-1 and GLP-2 may be secreted from prepoglucagon (PPG) neurons.
  • PPG prepoglucagon
  • GLP-1 and GLP-2 may be secreted from enteroendocrine L cells.
  • GLP-1 and GLP-2 may be secreted from their overexpressing cells.
  • each of GLP-1 and GLP-2 can be in the form of peptide fragments that include one or more receptor binding domains.
  • GLP-1 can be in the form of a peptide fragment that includes a GLP-1R binding domain.
  • GLP-2 can be in the form of a peptide fragment that includes a GLP-2R binding domain.
  • GLP-1 and GLP-2 can be in the form of separated peptides.
  • GLP-1 and GLP-2 can be linked to one another by a linking agent.
  • peptide fragments of GLP-1 and GLP-2 that include one or more receptor binding domains are linked to one another.
  • a GLP-1R- specific binding amino acid sequence and a GLP-2R- specific binding amino acid sequence are genetically or chemically linked to one another as a dual agonist to activate both GLP-1R and GLP-2R.
  • the therapeutic compositions of the present disclosure may be in various forms.
  • the therapeutic compositions of the present disclosure may be in the form of a liquid, a solid, a gas, and combinations thereof.
  • the therapeutic compositions of the present disclosure may be in the form of a liquid, such as a syrup.
  • the therapeutic compositions of the present disclosure may be in the form of a solid, such as a pill.
  • the therapeutic compositions of the present disclosure may also include components in addition to GLP-1 and GLP-2.
  • the therapeutic compositions of the present disclosure can also include other active agents.
  • the other active agents can include, without limitation, peptides, hormones, chemicals, and combinations thereof.
  • the therapeutic compositions of the present disclosure also include a carrier.
  • the carrier includes, without limitation, carbon-based nanomaterials, liposomes, polymers, micelles, microspheres, nanostructures, dendrimers, homing peptides, homing proteins (e.g., antibodies), and combinations thereof.
  • the therapeutic compositions of the present disclosure include GLP-1 as a carrier that serves as a homing peptide for central delivery of agonists or activators to activate GLP-1 -producing neurons in the brainstem NTS.
  • the therapeutic compositions of the present disclosure include GLP-IR as a homing peptide for central delivery of agonists or activators to activate GLP-lR-expressing neurons in the brainstem DMV.
  • the therapeutic compositions of the present disclosure also include formulation materials for modifying, maintaining, or preserving various parameters (e.g., pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution, rate of release, rate of adsorption, rate of penetration, and combinations thereof).
  • various parameters e.g., pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution, rate of release, rate of adsorption, rate of penetration, and combinations thereof.
  • suitable formulation materials can include, without limitation, amino acids (e.g., glycine), antimicrobials, antioxidants (e.g., ascorbic acid), buffers (e.g., Tris-HCl), bulking agents (e.g., mannitol and glycine), chelating agents (e.g., EDTA), complexing agents (e.g., hydroxypropyl-beta-cyclodextrin), and combinations thereof.
  • amino acids e.g., glycine
  • antimicrobials e.g., ascorbic acid
  • buffers e.g., Tris-HCl
  • bulking agents e.g., mannitol and glycine
  • chelating agents e.g., EDTA
  • complexing agents e.g., hydroxypropyl-beta-cyclodextrin
  • the administration occurs by methods that include, without limitation, oral administration, inhalation, subcutaneous administration, intravenous administration, intraperitoneal administration, intramuscular administration, intrathecal injection, topical administration, central administration, peripheral administration, and combinations thereof.
  • the administration occurs by intravenous administration.
  • the administration occurs by central administration.
  • the administration occurs by peripheral administration.
  • the subject is a human being.
  • the subject has been selected for or undergone bariatric surgery, such as roux-en- Y gastric bypass (RYGB) or vertical sleeve gastrectomy (VSG).
  • the subject is a non-human animal.
  • the non-human animal includes, without limitation, mice, rats, rodents, mammals, cats, dogs, monkeys, pigs, cattle and horses.
  • the subject suffers from a metabolic disorder, a metabolic syndrome, or a metabolic disease.
  • the subject suffers from a metabolic disease, such as nonalcoholic steatohepatitis (NASH), short-bowel syndrome (SBS), or combinations of such diseases.
  • NASH nonalcoholic steatohepatitis
  • SBS short-bowel syndrome
  • the methods and therapeutic compositions of the present disclosure may be utilized to treat or prevent various metabolic disorders, diseases or syndromes. In some embodiments, the methods and therapeutic compositions of the present disclosure may be utilized to treat various metabolic disorders, diseases or syndromes. In some embodiments, the methods and therapeutic compositions of the present disclosure may be utilized to prevent various metabolic disorders, diseases or syndromes. In some embodiments, the methods and therapeutic compositions of the present disclosure may be utilized to treat and prevent various metabolic disorders, diseases or syndromes. In some embodiments, the methods and therapeutic compositions of the present disclosure may be utilized to treat and prevent nonalcoholic steatohepatitis (NASH) and short- bowel syndrome (SBS).
  • NASH nonalcoholic steatohepatitis
  • SBS short- bowel syndrome
  • the methods and therapeutic compositions of the present disclosure may be utilized to treat or prevent metabolic syndromes.
  • the metabolic syndromes to be treated or prevented include, without limitation, insulin resistance, insulin sensitivity, glucose intolerance, and combinations thereof.
  • the methods and therapeutic compositions of the present disclosure may be utilized to treat or prevent metabolic diseases.
  • the metabolic diseases to be treated or prevented can include, without limitation, obesity, diabetes (e.g., type II diabetes), non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), short-bowel syndrome (SBS), intestinal deficiency of nutrient absorption after bariatric surgery, and combinations thereof.
  • the methods and therapeutic compositions of the present disclosure may be utilized to treat or prevent metabolic disorders.
  • the metabolic disorders to be treated or prevented can include, without limitation, hyperphagia, hyperglycemia, postprandial hyperglycemia, hyperlipidemia, abnormal cholesterol levels, hypertension, increased blood pressure, excess body fat mass, body adiposity, intestinal deficiency of nutrient absorption, and combinations thereof.
  • the methods and therapeutic compositions of the present disclosure may treat or prevent metabolic disorders, diseases and syndromes by various mechanisms.
  • the administering of the therapeutic compositions of the present disclosure to a subject can result in the dual activation of the GLP-1 and GLP-2 receptors in the cells of the subject (GLP-IR and GLP-2R, respectively) (step 12).
  • the dual activation of GLP-IR and GLP-2R can result in the treatment (step 14) or prevention (step 16) of metabolic disorders, diseases or syndromes.
  • the methods and therapeutic compositions of the present disclosure can be utilized to activate GLP-1R and GLP2-R in various cells by administering various combinations of exogenous GLP-1 and GLP-2 and their derivatives to a subject.
  • the administration of the therapeutic compositions of the present disclosure can treat or prevent metabolic disorders, diseases or syndromes by inducing various physiological effects in subjects.
  • physiological effects can include, without limitation, augmentation of pancreatic insulin secretion, enhancement of intestinal cell proliferation, improvement of insulin sensitivity (e.g., restoration or enhancement of insulin sensitivity), improvement of glucose intolerance, preservation of glucose homeostasis (e.g., reducing endogenous glucose production and fasting glucose), deceleration in gastric emptying, decrease in body fat accumulation, decrease in hepatic steatosis and inflammation, decrease in food intake, decrease in blood pressure, improvement of intestinal blood flow and circulation, enhancement of intestinal adaption (absorption), and combinations thereof.
  • the administration of the therapeutic compositions of the present disclosure can treat or prevent metabolic disorders, diseases or syndromes by improving insulin sensitivity in subjects. In some embodiments, the administration of the therapeutic compositions of the present disclosure can treat or prevent metabolic disorders, diseases or syndromes by preserving glucose homeostasis in subjects.
  • the methods and therapeutic compositions of the present disclosure can have various applications.
  • the administration of the therapeutic compositions of the present disclosure can improve glucose intolerance and insulin resistance associated with obesity, type II diabetes, and various metabolic syndromes.
  • the administration of the therapeutic compositions of the present disclosure can prevent postprandial hyperglycemia associated with obesity, type II diabetes, and various metabolic syndromes.
  • the administration of the therapeutic compositions of the present disclosure can reduce endogenous glucose production (gluconeogenesis) and fasting glucose associated with obesity, type II diabetes, and various metabolic syndromes.
  • the administration of the therapeutic compositions of the present disclosure can reverse non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) associated with obesity, type II diabetes, and various metabolic syndromes.
  • NAFLD non-alcoholic fatty liver disease
  • NASH nonalcoholic steatohepatitis
  • the administration of the therapeutic compositions of the present disclosure can reverse body adiposity (e.g., by decreasing body fat accumulation and food intake) and improve body composition in subjects associated with obesity, type II diabetes, and various metabolic syndromes.
  • the administration of the therapeutic compositions of the present disclosure can improve hypertension (e.g., by decreasing blood pressure) in subjects associated with obesity, type II diabetes, and various metabolic syndromes.
  • the administration of the therapeutic compositions of the present disclosure can improve intestinal blood flow and intestinal adaptation after bariatric surgery.
  • the central and peripheral administration of the therapeutic compositions of the present disclosure can prevent and treat various metabolic disorders.
  • the administration of the therapeutic compositions of the present disclosure can improve glycemic control and restore insulin sensitivity in obesity and diabetes.
  • the administration of the therapeutic compositions of the present disclosure can augment intestinal cell proliferation and absorption in total parental nutrition, short bowel syndrome, and intestinal function after bariatric surgery.
  • the central and peripheral administration of the therapeutic compositions of the present disclosure can prevent and treat various intestinal deficiency.
  • the central and peripheral administration of the therapeutic compositions of the present disclosure can be used to enhance intestinal adaptation and absorption after intestinal resection or bariatric surgery.
  • Example 1 Use of GLP-1 -producing neurons for the control of glucose homeostasis and insulin sensitivity
  • PPG prepoglucagon
  • a pharmacogenetics mouse model for the remote control activation of prepoglucagon (PPG) neurons in the brainstem in vivo was established.
  • Applicants generated a glucagon (Gcg) promoter-driven Cre transgenic mouse line in which Gcg-Cre expression was colocalized to GLP-1 -positive neurons in the brainstem.
  • DREADD designer receptors exclusively activated by designer drugs
  • Cre-dependent, excitatory AAV hM3Dq-mCherry vectors were injected into the brainstem NTS of 8-wk old Gcg-Cre mice.
  • validation of Gcg-Cre-dependent hM3Dq activation was established.
  • hM3Dq expression in the brainstem was performed using a Gcg-Cre:Rosa26eGFP reporter mice, in which hM3Dq-mCherry was faithfully expressed in GFP-positive neurons (identified by Gcg-Cre mediated eGFP).
  • excitation of hM3Dq-mCherry expressing neurons was confirmed by the whole cell patch clamp.
  • Membrane potential and firing rate of Gcg-Cre: hM3Dq-mCherry NTS neurons were recorded in brain slices.
  • GLP-1 and GLP-2 were released from activated PPG neurons.
  • the hM3Dq receptors rapidly activated infected PPG neurons in vivo.
  • a pharmacogenetics mouse model for the remote activation of PPG neurons in vivo was established through the following steps.
  • Glucagon (Gcg) promoter-driven Cre transgenic mouse line was generated and confirmed with GLP-1 immuno staining.
  • Remote activation of the NTS PPG neurons in the mouse model was created using the DREADD approach.
  • Cre- dependent, excitatory AAV hM3Dq-mCherry vectors were injected into the brainstem NTS of 8 wk-old, Gcg-Cre mice using stereotaxic coordinates.
  • Gcg Cre-dependent hM3Dq activation was validated by the following methods.
  • the hM3Dq expression in the brainstem was validated using Gcg-Cre: :Rosa26-eGFP reporter mice.
  • Acute activation of hM3Dq-expressing neurons was confirmed by the whole cell patch clamp.
  • Membrane potential and firing rate of Gcg-Cre: :hM3Dq-mCherry NTS neurons were recorded in brains slices.
  • Metabolic significance of remote activation of PPG neurons in the brainstem was determined as follows. Remote activation of hM3Dq-expressing neurons-mediated neural circuitry was mapped by c-Fos immunostaining in the brain after ip injection of clozapine N- oxide (CNO). Upon CNO stimulus, the hM3Dq receptors rapidly activated infected PPG neurons in vivo. Glucose tolerance tests and hyperinsulinemic euglycemic clamps were employed to quantify glucose homeostasis and insulin sensitivity in conscious Gcg-Cre mice after Cre- dependent hM3Dq vectors were injected into their brainstem NTS.
  • CNO clozapine N- oxide
  • a dual stable isotopic tracer method for hyperinsulinemic euglycemic clamp was developed as follows. Mice were continuously infused with 6,6- H 2 -D-glucose via a jugular catheter for 3 hours during a basal period and then for 3 hours during an insulin clamp (FIG. 5), whereas 6,6- H 2 -D-glucose plus D-glucose were infused to maintain blood glucose level. Deuterium enrichments of glucose were measured after derivatization using GC-MS. Glucose kinetics was quantified at a steady-state in conscious mice.
  • FIG. 2 shows the results of PPG neurons-mediated neural circuitry in the brainstem.
  • autonomic PPG neurons were labeled by Gcg promoter-driven eGFP (green) in the mouse brainstem NTS.
  • Glp2r neurons were immunostained (green) where PPG neurons widely project.
  • Phox2b neurons were labeled by Cre- dependent, Rosa26-td Tomato reporter (red).
  • FIGURE 3 shows that the generated Gcg-Cre transgenic mouse line was validated by Cre-dependent Rosa26-eGFP reporter mouse.
  • Gcg-Cre-mediated GFP expression was shown in distinct neurons in the brainstem NTS (FIG. 3A) and enteroendocrine cells in the gut (FIG. 3B).
  • GFP-expressing cells were GLP-l/2-immunopositive.
  • FIGURE 4 shows data relating to the remote activation of Cre-dependent hM3Dq- expressing PPG neurons, as indicated by c-Fos expression.
  • FIG. 4A a weak c- Fos expression was observed in the basal without CNO injection.
  • FIG. 4B shows a symbolized map of the brainstem area.
  • FIG. 4C shows that c-Fos expression was increased at 30 minutes after CNO injection.
  • FIG. 4D shows an enlarged image of the squared region in FIG. 4C.
  • the c-Fos-positive cells green
  • were largely segregated from hM3Dq-expressing cells red).
  • FIGURE 6 illustrates the activation of hM3Dq-expressing PPG neurons induced acutely by CNO.
  • PPG neurons were indicated by mCherry (red) in the brainstem NTS from the Gcg-Cre mouse locally infected with AAV hM3Dq-mCherry vectors with c-Fos expression (green).
  • hM3Dqexpressing PPG neurons excited by CNO (5 ⁇ ) showed representative traces of the whole-cell patch clamp.
  • FIG. 6C PPG neurons were labeled by GFP (green) from the Gcg-Cre::Rosa26-eGFP mouse brainstem.
  • FIG. 6D shows the location of the brainstem slice.
  • FIGURE 7 demonstrates that the remote activation of PPG neurons enhances glucose tolerance and insulin sensitivity in mice fed regular chow.
  • FIG. 7A shows data relating to a 6 hour fasting glucose at 0 and 3.5 hours after injection of CNO (ip 1 mg/kg).
  • CNO ip 1 mg/kg
  • AAVhM3Dq- mCherry vectors 100 nL were injected into the Gcg-Cre mouse brainstem NTS.
  • FIG. 7B shows blood glucose concentration of mice (at 3 weeks post viral injection). The blood glucose concentration was measured after an ip glucose challenge.
  • CNO was ip injected 30 minutes prior to ipGTT.
  • FIG. 7C shows data relating to endogenous glucose production (EGP) during a basal period in the mice (at 3 weeks post viral injection).
  • FIG. 7D shows insulin sensitivity of the conscious mice (at 3 weeks post viral injection) quantified by hyperinsulinemic euglycemic clamp coupled with dual stable isotopic tracers
  • FIGURE 8 shows that the remote activation of ChAT neurons in the DVC enhances hepatic insulin sensitivity in mice that were fed regular chow.
  • FIG. 8A shows ChAT neurons labeled by ChAT-Cre-mediated tdTomato (red) in the brainstem DVC from a ChAT Cre::Rosa26-tdTomato reporter mouse.
  • FIG. 8B shows GLP-2R colocalized to ChAT neurons in the DVC.
  • FIG. 8C shows a protocol for quantifying insulin sensitivity in mice with remote activation of the DVC ChAT neurons.
  • AAV-hM3Dq-mCherry vectors were injected into the ChAT Cre mouse brainstem DMV.
  • FIG. 8D shows insulin sensitivity of the conscious mice quantified by hyperinsulinemic eyglycemic clamp coupled with dual stable isotopic tracers (FIG. 5).
  • Remote activation of ChAT neurons augments insulin sensitivity by further suppression of endogenous glucose production.
  • ChAT Cre mouse line is confirmed in Cre-mediated Rosa26-td-Tomato reporter and GLP-2R-immunoreactive neurons stained by immunohistochemistry, indicating GLP-2R-postive neurons are ChAT neurons in the brainstem.
  • NTS PPG neurons can be remotely activated with the DREADD approach, as confirmed by c-Fos expression after ip CNO.
  • the NTS PPG neurons infected with AAV hM3Dq particles can be acutely excited ex vivo upon CNO application. It is assumed that the hM3Dq activation would rapidly excite infected PPG neurons.
  • remote activation of either PPG neurons (i.e., GLP-1 -producing neurons) or ChAT neurons (i.e., GLP-2R-expressing neurons) improves glucose tolerance and insulin sensitivity, suggesting that PPG-ChAT autonomic circuitry plays an important role in glycemic control and insulin sensitivity.
  • activation of the NTS PPG neurons improves glycemic control and insulin sensitivity via fine-tuning autonomic outputs to peripheral tissues (liver), thereby suppressing hepatic glucose production (HGP), which involves Glplr/2r-positive, ChAT neurons in the brainstem DMV.
  • HGP hepatic glucose production
  • Example 2 GLP-1R/2R dual activation for improving postprandial glycemic control and insulin sensitivity in DIO mice after VSG
  • Applicants provide data indicating that GLP-1R/2R dual activation is needed for improving postprandial glycemic control (PGC) and insulin sensitivity (IS); essential for improving non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH); and required for intestinal adaptation after bariatric surgery in diet-induced obese mice (DIO mice) after vertical sleeve gastrectomy (VSG).
  • PPC postprandial glycemic control
  • IS insulin sensitivity
  • NASH non-alcoholic fatty liver disease
  • NASH nonalcoholic steatohepatitis
  • VSG vertical sleeve gastrectomy
  • Mice with GLP1R/2R double knockout (DKO) displayed postprandial hyperglycemia and postabsorptive insulin sensitivity (FIG. 10).
  • the DKO mice fed high-fat diet (HFD) showed severe glucose intolerance after gavage feeding (FIG.
  • meal may be a physiological trigger (e.g., for glucose-sensing endocrine ⁇ cells in the pancreas and neurons in the brain) to initiate a negative-feedback neuroendocrine control of PGC.
  • a physiological trigger e.g., for glucose-sensing endocrine ⁇ cells in the pancreas and neurons in the brain
  • the DKO mice fed either HFD or regular chow had higher fasting glucose (FIG. 10F).
  • IS was further impaired in the DKO mice fed HFD as indicated by higher EGP and lower Rd during the insulin clamp (FIG. 10G).
  • Body weight and fat mass increased in the DKO (FIG. 10H) due to reduced basal metabolic rate and increased feeding. This metabolic phenotype of the DKO mouse indicates that endogenous GLP1R/2R play an essential role in PGC and IS.
  • FIG. 12 The data in FIG. 12 demonstrates that the dual activation of endogenous GLP-1R/2R is necessary for VSG to restore postprandial glycemic control in DIO mice.
  • Postprandial glucose intolerance induced by HFD was improved after VSG only in the wild type (WT) mice, not the DKO mice (FIG. 12A).
  • the amount of glucose in the whole body was significantly decreased at the baseline and postprandial state after VSG in the WT mice, but not the DKO mice) (data not shown).
  • Rd might represent insulin-stimulated rapid translocation of glucose transporters responsible for uptake in adipose/muscle tissues, while GNG would result from insulin-inhibited transcription of gluconeogenic genes in the liver.
  • VSG- improved postprandial glycemic kinetics was blunted in the DKO mice.
  • the data in FIG. 13 demonstrates that the dual activation of endogenous GLP-1R/2R is necessary for VSG to improve postabsorptive insulin sensitivity in DIO mice. In the WT, VSG reduced basal glucose after a 12 hour fast (FIG.
  • FIG. 14 The data in FIG. 14 demonstrates that the dual activation of endogenous GLP-1R/2R are required for intestinal adaptation in DIO mice after VSG.
  • VSG showed intestinal adaptation by increased intestinal proliferative index (FIGS. 14 A-D).
  • VSG-augmented intestinal proliferation was fully blunted in the DKO DIO mice (FIGS. 14 E-F), suggesting that the dual activation of GLP-1R/2R is necessary for VSG-induced intestinal adaptation and prevented intestinal deficiency from bariatric surgery.
  • FIG. 15 demonstrates that the double knockout of endogenous GLP-1R/2R shows high incidence of hepatic steatosis and inflammation (i.e., nonalcoholic steatohepatitis (NASH)) in DIO mice. Histological inflammation and fibrosis is characterized only in the liver from the DIO mouse with DKO (FIG. 15 B) while hepatic steatosis is shown in both WT (FIG. 15 A) and DKO.
  • the data indicate that endogenous GLP-1R/2R are important for pathological progression of NAFLD to NASH.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Selon des modes de réalisation, la présente invention concerne des compositions thérapeutiques qui comprennent à la fois un peptide 1 de type glucagon 1 (GLP -1) et un peptide de type glucagon 2 (GLP-2) pour le traitement ou la prévention d'une maladie métabolique, d'un trouble métabolique ou d'un syndrome métabolique chez un sujet. Chacun des GLP-1 et GLP-2 peut se présenter sous la forme de peptides synthétisés, de peptides recombinants, de peptides sécrétés, de peptides isolés, de peptides lyophilisés, de peptides dérivés, des peptides intacts, de fragments peptidiques qui comprennent un ou plusieurs domaines de liaison au récepteur, et des combinaisons de ceux-ci. Des modes de réalisation supplémentaires concernent des procédés de traitement ou de prévention de maladies, troubles ou syndromes métaboliques chez un sujet par l'administration des compositions thérapeutiques de la présente invention au sujet.
PCT/US2017/041075 2016-07-07 2017-07-07 Combinaison de glp-1 et de glp-2 pour le traitement ou la prévention de maladies, troubles et syndromes métaboliques WO2018009778A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359413P 2016-07-07 2016-07-07
US62/359,413 2016-07-07

Publications (1)

Publication Number Publication Date
WO2018009778A1 true WO2018009778A1 (fr) 2018-01-11

Family

ID=60913204

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/041075 WO2018009778A1 (fr) 2016-07-07 2017-07-07 Combinaison de glp-1 et de glp-2 pour le traitement ou la prévention de maladies, troubles et syndromes métaboliques

Country Status (1)

Country Link
WO (1) WO2018009778A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082507A1 (en) * 2000-09-18 2004-04-29 Henriksen Dennis B. Use of GLP-1 and GLP-2 peptides
WO2011163012A2 (fr) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d'amides de la superfamille du glucagon
US20130059780A1 (en) * 2004-07-13 2013-03-07 Biogenerix Ag Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US20140243263A1 (en) * 2007-11-23 2014-08-28 Michael Rothkopf Method of enhancing diabetes resolution
US20150011919A1 (en) * 2012-03-30 2015-01-08 Ethicon Endo-Surgery, Inc. Devices and methods for the treatment of metabolic disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040082507A1 (en) * 2000-09-18 2004-04-29 Henriksen Dennis B. Use of GLP-1 and GLP-2 peptides
US20130059780A1 (en) * 2004-07-13 2013-03-07 Biogenerix Ag Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
US20140243263A1 (en) * 2007-11-23 2014-08-28 Michael Rothkopf Method of enhancing diabetes resolution
WO2011163012A2 (fr) * 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Promédicaments peptidiques à base d'amides de la superfamille du glucagon
US20150011919A1 (en) * 2012-03-30 2015-01-08 Ethicon Endo-Surgery, Inc. Devices and methods for the treatment of metabolic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FINAN ET AL.: "Emerging opportunities for the treatment of metabolic diseases: Glucagon-like peptide-1 based multi-agonists", MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 418, 15 December 2015 (2015-12-15), pages 42 - 54, XP055450181 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11512065B2 (en) 2019-10-07 2022-11-29 Kallyope, Inc. GPR119 agonists
US11279702B2 (en) 2020-05-19 2022-03-22 Kallyope, Inc. AMPK activators
US11851429B2 (en) 2020-05-19 2023-12-26 Kallyope, Inc. AMPK activators
US11407768B2 (en) 2020-06-26 2022-08-09 Kallyope, Inc. AMPK activators

Similar Documents

Publication Publication Date Title
Drucker GLP-1 physiology informs the pharmacotherapy of obesity
Duca et al. The metabolic impact of small intestinal nutrient sensing
Janssen et al. a comparison of glucagon‐like peptides 1 and 2
Rowland et al. The “cryptic” mechanism of action of glucagon-like peptide-2
Karra et al. The role of gut hormones in the regulation of body weight and energy homeostasis
Sam et al. The role of the gut/brain axis in modulating food intake
Bauer et al. Regulation of energy balance by a gut–brain axis and involvement of the gut microbiota
Marathe et al. Glucagon-like peptides 1 and 2 in health and disease: a review
Perry et al. Appetite regulation and weight control: the role of gut hormones
Sun et al. The regulation of peripheral metabolism by gut-derived hormones
Baggio et al. Biology of incretins: GLP-1 and GIP
Brandt et al. Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology
Adamska et al. The role of gastrointestinal hormones in the pathogenesis of obesity and type 2 diabetes
Brubaker Glucagon‐like peptide‐2 and the regulation of intestinal growth and function
Krieger et al. Vagal mediation of GLP-1's effects on food intake and glycemia
Parlevliet et al. GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet
De Heer et al. The alpha cell expresses glucagon-like peptide-2 receptors and glucagon-like peptide-2 stimulates glucagon secretion from the rat pancreas
WO2018009778A1 (fr) Combinaison de glp-1 et de glp-2 pour le traitement ou la prévention de maladies, troubles et syndromes métaboliques
Kabahizi et al. Glucagon‐like peptide‐1 (GLP‐1) signalling in the brain: From neural circuits and metabolism to therapeutics
Salehi et al. The role of glucagon-like peptide-1 in energy homeostasis
Tong et al. Is the GLP-1 system a viable therapeutic target for weight reduction?
Conchillo et al. Insulin-like growth factor I (IGF-I) and liver cirrhosis
Kokkinos et al. Will medications that mimic gut hormones or target their receptors eventually replace bariatric surgery?
Cariou Pleiotropic effects of insulin and GLP-1 receptor agonists: potential benefits of the association
JP6889154B2 (ja) グルカゴン類似ペプチド−１受容体亢進剤を含む筋減少症治療用薬学組成物

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17824966

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17824966

Country of ref document: EP

Kind code of ref document: A1